Periocular triamcinolone for prevention of macular edema after iodine 125 plaque radiotherapy of uveal melanoma

Retina

Volumn 28, Issue 7, 2008, Pages 987-995

  Horgan, Noel ^a   Shields, Carol L ^a,c   Mashayekhi, Arman ^a   Teixeira, Luiz F ^a   Materin, Miguel A ^a   O'regan, Myra ^b   Shields, Jerry A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c WILLS EYE HOSPITAL   (United States)

Author keywords

Choroid; Corticosteroid; Eye; Macular edema; Melanoma; Optical coherence tomography; Plaque radiotherapy; Triamcinolone; Uvea; Vascular endothelial growth factor

Indexed keywords

IODINE 125; TRIAMCINOLONE;

ADULT; ARTICLE; CATARACT; CONTROLLED STUDY; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; PTOSIS; RETINA MACULA EDEMA; RISK REDUCTION; UVEA MELANOMA; VISUAL IMPAIRMENT;

BRACHYTHERAPY; FEMALE; GLUCOCORTICOIDS; HUMANS; INJECTIONS; IODINE RADIOISOTOPES; MACULA LUTEA; MACULAR EDEMA; MALE; MELANOMA; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RADIATION INJURIES; TRIAMCINOLONE ACETONIDE; UVEAL NEOPLASMS; VITREOUS BODY;

EID: 67649658508     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31816b3192     Document Type: Article

References (47)

1. Bartlema YM, Oosterhuis JA, Journee-De Korver JG, et al. Combined plaque radiotherapy and transpupillary thermotherapy in choroidal melanoma: 5 years' experience. Br J Ophthalmol 2003;87:1370-1373.
2. Shields CL, Shields JA, Gunduz K, et al. Radiation therapy for uveal malignant melanoma. Ophthalmic Surg Lasers 1998;29:397-409.
3. Shields CL, Cater J, Shields JA, et al. Combined plaque radiotherapy and transpupillary thermotherapy for choroidal melanoma: tumor control and treatment complications in 270 consecutive patients. Arch Ophthalmol 2002;120:933-940.
4. Shields CL, Shields JA, Cater J, et al. Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients. Arch Ophthalmol 2000;118:1219-1228.
5. Gunduz K, Shields CL, Shields JA, et al. Radiation complications and tumor control after plaque radiotherapy of choroidal melanoma with macular involvement. Am J Ophthalmol 1999;127:579-589.
6. Gunduz K, Shields CL, Shields JA, et al. Radiation retinopathy following plaque radiotherapy for posterior uveal melanoma. Arch Ophthalmol 1999;117:609-614.
7. Mukai SGD, Gragoudas ES. Radiation retinopathy. In: Albert DMJF, ed. Principles and Practice of Ophthalmology. Vol 2. Philadelphia: WB Saunders; 1994:1038-1041.
8. Horgan N, Shields CL, Mashayekhi A, et al. Early macular morphological changes following plaque radiotherapy for uveal melanoma. Retina 2008;28:263-273.
9. Yoshikawa K, Kotake S, Ichiishi A, et al. Posterior sub-Tenon injections of repository corticosteroids in uveitis patients with cystoid macular edema. Jpn J Ophthalmol 1995; 39:71-76.
10. Bakri SJ, Kaiser PK. Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema. Am J Ophthalmol 2005;139:290-294.
11. Early Treatment of Diabetic Retinopathy Study Group. Photocoagulation for macular edema, Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985; 103:1796-1806.
12. Brown GC, Shields JA, Sanborn G, et al. Radiation retinopathy. Ophthalmology 1982;89:1494-1501.
13. Brown GC, Shields JA, Sanborn G, et al. Radiation optic neuropathy. Ophthalmology 1982;89:1489-1493.
14. Tranos PG, Wickremasinghe SS, Stangos NT, et al. Macular edema. Surv Ophthalmol 2004;49:470-490.
15. Guyer DR, Mukai S, Egan KM, et al. Radiation maculopathy after proton beam irradiation for choroidal melanoma. Ophthalmology 1992;99:1278-1285.
16. Antcliff RJ, Spalton DJ, Stanford MR, et al. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 2001;108:765-772.
17. Gillies MC, Sutter FK, Simpson JM, et al. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006;113:1533-1538.
18. Ciardella AP, Klancnik J, Schiff W, et al. Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study. Br J Ophthalmol 2004;88:1131-1136.
19. Larsson J, Zhu M, Sutter F, Gillies MC. Relation between reduction of foveal thickness and visual acuity in diabetic macular edema treated with intravitreal triamcinolone. Am J Ophthalmol 2005;139:802-806.
20. Degenring RF, Kamppeter B, Kreissig I, Jonas JB. Morphological and functional changes after intravitreal triamcinolone acetonide for retinal vein occlusion. Acta Ophthalmol Scand 2003;81:548-550.
21. Okada AA, Wakabayashi T, Morimura Y, et al. Trans-Tenon's retrobulbar triamcinolone infusion for the treatment of uveitis. Br J Ophthalmol 2003;87:968-971.
22. Wakabayashi T, Okada AA, Morimura Y, et al. Trans-Tenon retrobulbar triamcinolone infusion for chronic macular edema in central and branch retinal vein occlusion. Retina 2004;24:964-967.
23. Helm CJ, Holland GN. The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis. Am J Ophthalmol 1995;120:55-64.
24. Tunc M, Onder HI, Kaya M. Posterior sub-Tenon's capsule triamcinolone injection combined with focal laser photocoagulation for diabetic macular edema. Ophthalmology 2005; 112:1086-1091.
25. Uckermann O, Kutzera F, Wolf A, et al. The glucocorticoid triamcinolone acetonide inhibits osmotic swelling of retinal glial cells via stimulation of endogenous adenosine signaling. J Pharmacol Exp Ther 2005;315:1036-1045.
26. Brooks HL Jr, Caballero S Jr, Newell CK, et al. Vitreous levels of vascular endothelial growth factor and stromalderived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Arch Ophthalmol 2004;122:1801-1807.
27. Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of bloodretinal and blood-aqueous barrier breakdown. Exp Eye Res 2005;80:249-258.
28. Angunawela RI, Heatley CJ, Williamson TH, et al. Intravitreal triamcinolone acetonide for refractory uveitic cystoid macular oedema: long-term management and outcome. Acta Ophthalmol Scand 2005;83:595-599.
29. Tolentino MJ, Prenner JL, Gendron EK, Maguire AM. Echographic localisation of corticosteroid after retrobulbar injection. Br J Ophthalmol 2001;85:626-627.
30. Freeman WR, Green RL, Smith RE. Echographic localization of corticosteroids after periocular injection. Am J Ophthalmol 1987;103:281-288.
31. Thach AB, Dugel PU, Flindall RJ, et al. A comparison of retrobulbar versus sub-Tenon's corticosteroid therapy for cystoid macular edema refractory to topical medications. Ophthalmology 1997;104:2003-2008.
32. Thomas ER, Wang J, Ege E, et al. Intravitreal triamcinolone acetonide concentration after subtenon injection. Am J Ophthalmol 2006;142:860-861.
33. Hayashi K, Hayashi H. Intravitreal versus retrobulbar injections of triamcinolone for macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2005;139: 972-982.
34. Bonini-Filho MA, Jorge R, Barbosa JC, et al. Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial. Invest Ophthalmol Vis Sci 2005;46:3845-3849.
35. D'Amico DJ, Masonson HN, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006;113:992-1001.
36. Vinores SA, Kuchle M, Mahlow J, et al. Blood-ocular barrier breakdown in eyes with ocular melanoma. A potential role for vascular endothelial growth factor/vascular permeability factor. Am J Pathol 1995;147:1289-1297.
37. Stitt AW, Simpson DA, Boocock C, et al. Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intra-ocular tumours. J Pathol 1998; 186:306-312.
38. Ijland SA, Jager MJ, Heijdra BM, et al. Expression of angiogenic and immunosuppressive factors by uveal melanoma cell lines. Melanoma Res 1999;9:445-450.
39. Sheidow TG, Hooper PL, Crukley C, et al. Expression of vascular endothelial growth factor in uveal melanoma and its correlation with metastasis. Br J Ophthalmol 2000;84:750-756.
40. Missotten GS, Notting IC, Schlingemann RO, et al. Vascular endothelial growth factor a in eyes with uveal melanoma. Arch Ophthalmol 2006;124:1428-1434.
41. Boyd SR, Tan D, Bunce C, et al. Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window. Br J Ophthalmol 2002;86:448-452.
42. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-1309.
43. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989;246:1309-1312.
44. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611.
45. Lundberg I, Kratz AK, Alexanderson H, Patarroyo M. Decreased expression of interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis. Arthritis Rheum 2000;43:336-348.
46. Nyhlen K, Linden M, Andersson R, Uppugunduri S. Corticosteroids and interferons inhibit cytokine-induced production of IL-8 by human endothelial cells. Cytokine 2000;12:355-360.
47. Tamura H, Miyamoto K, Kiryu J, et al. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 2005;46:1440-1444.